GSK and Pfizer sign joint venture, but will demerge after three years
20-12-2018
© GSK
Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s (GSK) portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission (FTC), the agency has said.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FTC, Novartis, GSK, M&A, cancer, BRAF, MEK
